This course is no longer available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase.
It would need to be repurchased by the trainee if not completed in the allotted time period.
This course is no longer available.
You will need to repurchase if you wish to take the course again.

Description

New oncology therapeutics on the horizon: The clinical availability of species-specific oncology therapeutics for dogs and cats is rapidly expanding. This session reviews the science and clinical use of several current and future therapeutics for common canine and feline cancers. Discussion will highlight the potential impact these therapies may have on your patients in daily practice.

Objectives

Learning Objective 1

Become familiar with new veterinary oncology therapeutics which are currently available or will be in the near future with emphasis on:
-Mechanism of action
-Potential clinical uses in dogs and cats with cancer
-Known and potential side effects

Learning Objective 2

Review recent data on more established veterinary oncology therapeutics to aid in best clinical utilization

Learning Objective 3

Understand mechanism and potential role for new oncology supportive therapeutics and how they may positively impact case management and patient quality of life

Dr. Chad Johannes, DVM, DACVIM (SAIM, Oncology) is an Assistant Professor of Small Animal Internal Medicine and Oncology at Iowa State University. Having previously practiced in the primary and specialty care settings, his industry experience has included coordination of the launch of Palladia®, the first FDA-approved veterinary cancer therapeutic, and Medical Director at Aratana Therapeutics, Inc. Dr. Johannes’s career has focused on the compassionate care of chronic medical conditions, including cancer, in dogs and cats

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s: